202189-77-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)propan-2-yl)-4,4-dimethyl-4,5-dihydrooxazole is used as a potential pharmaceutical agent for its complex structure and the presence of various functional groups that may interact with biological targets, offering new avenues for drug development.
Used in Chemical Research:
In the field of chemical research, 2-(2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)propan-2-yl)-4,4-dimethyl-4,5-dihydrooxazole serves as a subject for studying the synthesis and properties of complex organic molecules. Its unique structure may provide insights into new chemical reactions and mechanisms, contributing to the advancement of organic chemistry.
Used in Material Science:
2-(2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)propan-2-yl)-4,4-dimethyl-4,5-dihydrooxazole may be utilized in material science for the development of new materials with specific properties. Its complex structure and functional groups could be leveraged to create materials with tailored characteristics for various applications.

Upstream product

• 202189-76-2 2-{4-[1-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-1-methylethyl]phenyl}ethyl p-toluenesulfonate 
• 1841081-72-8 1-(2-ethoxyethyl)-2-piperidin-4-yl-1H-benzimidazole hydrochloride 
• 38385-95-4 2-(4-piperidinyl)-1H-benzimidazole 
• 1841081-72-8 1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole dihydrochloride 
• 953071-73-3 tert-butyl 4-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate 
• 17178-11-9 2-ethoxyethyl p-toluenesulfonate 
• 361382-26-5 2-{1-[4-(2-hydroxyethyl)phenyl]-1-methylethyl}-4,5-2H-4,4-dimethyl-oxazole 

Downstream Products

• 202189-78-4 Bilastine 

Relevant academic research and scientific papers

Identification and synthesis of potential impurities of bilastine drug substance

Bilastine is a new, well-tolerated, nonsedating H1 receptor antihistamine. Herein, we describe the synthesis of four new potential impurities of bilastine, namely 2-[4-(2-(4-(1-(2-methoxyethyl)benzimidazole-2-yl) piperidine-1-yl)ethyl) phenyl]-2-methylpropanoic acid (2) (methoxyethyl bilastine), 2-[4-(2-(4-(1-(2-(2-ethoxyethoxy)ethyl)benzimidazole-2-yl) piperidine-1-yl)ethyl)phenyl]-2-methyl propanoic acid (3) ((2-ethoxyethoxy)ethyl bilastine), 2-amino-2-methylpropyl 2-[4-(2-(4-(1-(2-ethoxyethyl)benzimidazole-2-yl) piperidine-1-yl)ethyl)phenyl]-2-methyl propanoate (4) (2-amino-2-methylpropyl ester of bilastine or bilastine open-ring ester) and 2-[4-(2-(4-(1-(2-ethoxyethyl)benzimidazole-2-yl] piperidine-1-yl) ethyl) phenyl]-N-(1-hydroxy-2-methylpropan-2-yl)-2-methylpropanamide (5) [N-(1-hydroxy-2-methyl-2-propanyl)amide of bilastine or bilastine open-ring amide]. Each (2, 3, 4 and 5) is an observed process-related impurity with a possible significant impact on the quality of the drug product. This work is useful for generic pharmaceutical industry for making impurity reference standards. Pharmacopeia is not available for bilastine; hence, the control of these impurities in the API below the threshold level is essential as per International Conference on Harmonization (ICH) recommendations.

TITLE: PROCESS FOR THE PREPARATION OF BILASTINE

The present invention relates to a process for the preparation of bilastine, a compound of formula I. The present invention relates to p-xylene solvate of bilastine and process for its preparation. The present invention relates to a process for the prepar

A process for the preparation of the compared to the russ sandbank method (by machine translation)

The invention relates to a process for the preparation method compared to the russ sandbank, including I [...] compound added to the water, to add a phase transfer catalyst, paratoluene sulfonyl chloride and sodium hydroxide, after stirring and reacting and filtration to obtain [...] sulfonic acid ester. The sulfonic acid ester added to the water, by adding 2 - (4 - piperidinyl) 1 - H - benzimidazole and phase-transfer catalyst, adding sodium carbonate or potassium carbonate, heating suspension reaction 3 - 5 hours, filtering the obtained intermediate II is added to the strong polar non-protic solvent, by adding sodium hydroxide, phase-transfer catalyst, ethylene glycol is added to the toluene sulfonic acid ester, - 20 - 60° stirring reaction after the end of the filter and wash the obtained intermediate III. The intermediate III into the organic acid aqueous solution, refluxing 3 - 5 hours, water addition, adding alkali saturated, solution reflux 3 - 5 hours, generated in the saturated [...] does not dissolve in the alkaline solution, extraction [...]. The method of mild reaction conditions, the operation is simple, environmental protection, high yield, is suitable for industrial production. (by machine translation)

Bilastine intermediate preparation method

The present invention relates to a Bilasiting intermediate 2-[1-(2-{4-[1-(4,4-dimethyl-4,5-2H-oxazol-2-yl)-1-methyl-ethyl]-phenyl}-ethyl)-piperidin-4-yl]-1H-benzimidazole preparation method, the compound 2-{1-[4-(2-hydroxyethyl) phenyl]-1-methylethyl}-4,5-2H-4,4-dimethyl-oxazole is dissolved in an organic solvent, trifluoromethanesulfonyl chloride is dissolved, and added dropwise to the system, after the completion of the addition, triethylamine is added for heating and refluxing for 1h to obtain structure II compound 2-[4-(1-(4,4-dimethyl-2H-oxazol-2-yl)-1-methylethyl) phenyl] ethyl triflate, and the resulting compound 2-[4-(1-(4,4-dimethyl-2H-oxazol-2-yl)-1-methylethyl) phenyl] ethyl triflate is dissolved in an organic solvent, under nitrogen protection, sodium methoxide is added for reaction for 2 h, 2-(4-piperidine)-1 H-benzimidazole is added for heating and refluxing for 2h to obtain 2-[1-(2-{4-[1-(4,4-dimethyl-4,5-2H-oxazol-2-yl)-1-methyl-ethyl]-phenyl}-ethyl)-piperidin-4-yl]-1H-benzimidazole.